Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 13.8% in October

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 398,900 shares, a growth of 13.8% from the October 15th total of 350,600 shares. Based on an average trading volume of 116,700 shares, the short-interest ratio is currently 3.4 days.

Harvard Bioscience Stock Performance

Shares of HBIO stock traded up $0.06 during mid-day trading on Monday, hitting $2.20. The stock had a trading volume of 19,850 shares, compared to its average volume of 116,754. Harvard Bioscience has a fifty-two week low of $2.12 and a fifty-two week high of $5.56. The firm has a market cap of $95.96 million, a PE ratio of -6.48 and a beta of 1.31. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.94. The company’s 50-day simple moving average is $2.52 and its 200-day simple moving average is $2.89.

Hedge Funds Weigh In On Harvard Bioscience

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in shares of Harvard Bioscience by 2.2% during the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after buying an additional 19,972 shares in the last quarter. Barclays PLC lifted its position in Harvard Bioscience by 304.4% during the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 44,150 shares in the last quarter. State Street Corp lifted its position in shares of Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after purchasing an additional 7,763 shares in the last quarter. Harvey Partners LLC increased its stake in shares of Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after buying an additional 157,500 shares during the last quarter. Finally, Corsair Capital Management L.P. bought a new stake in shares of Harvard Bioscience in the third quarter worth $63,000. 80.87% of the stock is currently owned by hedge funds and other institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.